Gemcitabine, capecitabine, docetaxel followed by radiotherapy for Pancreatic Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Columbia University Medical Center, New York, NYPancreatic Cancer+1 MoreGemcitabine, capecitabine, docetaxel followed by radiotherapy - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study the safety and efficacy of a combination of Gemcitabine, Capecitabine, and Docetaxel in patients with locally advanced pancreatic cancer.

Eligible Conditions
  • Stage II Pancreatic Cancer
  • Stage III Pancreatic Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 2 years

12 weeks
To describe the effect of neoadjuvant GTX regimen on resectability for those with arterial involvement and those with venous involvement, separately
2 years
To determine the effect of neoadjuvant regimen of GTX on the 2-year disease free survival rate

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

Group I
1 of 2
Group II
1 of 2

Experimental Treatment

64 Total Participants · 2 Treatment Groups

Primary Treatment: Gemcitabine, capecitabine, docetaxel followed by radiotherapy · No Placebo Group · Phase 2 & 3

Group I
Drug
Experimental Group · 1 Intervention: Neoadjuvant gemcitabine, capecitabine, and docetaxel · Intervention Types: Drug
Group II
Drug
Experimental Group · 1 Intervention: Gemcitabine, capecitabine, docetaxel followed by radiotherapy · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

Columbia UniversityLead Sponsor
1,317 Previous Clinical Trials
1,623,925 Total Patients Enrolled
William Sherman, MDPrincipal InvestigatorColumbia University

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Your tumor cannot be removed through surgery because it is too close to important blood vessels.

Frequently Asked Questions

Are there any other ongoing trials that are testing the combination of Gemcitabine, capecitabine, and docetaxel before radiotherapy?

"As of right now, there are 1057 active studies for Gemcitabine, capecitabine, docetaxel followed by radiotherapy. Of these, 358 are in Phase 3. With several trials for Gemcitabine, capecitabine, docetaxel followed by radiotherapy running out of in Guangzhou, Guangdong, there are still a total of 53306 locations operating trials for Gemcitabine, capecitabine, docetaxel followed by radiotherapy." - Anonymous Online Contributor

Unverified Answer

Are there any spots still open in this research project?

"This study is not actively recruiting patients at this moment. The listing was originally created on December 1st, 2009 and was most recently edited on January 27th, 2014. If you are looking for other studies, 594 trials for cancer of the pancreas and 1057 for Gemcitabine, capecitabine, docetaxel followed by radiotherapy are still admitting patients." - Anonymous Online Contributor

Unverified Answer

What condition is the Gemcitabine, capecitabine, docetaxel followed by radiotherapy treatment most often used to improve?

"Gemcitabine, capecitabine, and docetaxel followed by radiotherapy is a common treatment for patients that have received adjuvant anthracycline-containing therapy. This treatment method is also effective for patients suffering from conditions such as head and soft tissue sarcoma, as well as colorectal carcinoma." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.